Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration

被引:7
|
作者
Kijtawornrat, Anusak [1 ,4 ]
Komolvanich, Siripen [1 ]
Saengklub, Nakkawee [2 ]
Pirintr, Prapawadee [3 ]
Boonpala, Pakit [1 ]
Buranakarl, Chollada [1 ]
机构
[1] Chulalongkorn Univ, Fac Vet Sci, Dept Physiol, Henri Dunant Rd, Bangkok 10330, Thailand
[2] Mahidol Univ, Fac Pharm, Dept Physiol, Bangkok 10400, Thailand
[3] Chiang Mai Univ, Fac Vet Med, Dept Vet Biosci & Vet Publ Hlth, Chiang Mai 50100, Thailand
[4] Chulalongkorn Univ, Res Clusters Res Study & Testing Drugs Effect Rel, Bangkok 10330, Thailand
来源
JOURNAL OF VETERINARY MEDICAL SCIENCE | 2017年 / 79卷 / 04期
关键词
asymptomatic; dog; echocardiography; mitral valve degeneration; sildenafil; CONGESTIVE-HEART-FAILURE; NATRIURETIC PEPTIDE CONCENTRATION; PULMONARY-HYPERTENSION; VALVULAR DISEASE; INHIBITION; THERAPY; IMPROVES; CITRATE;
D O I
10.1292/jvms.16-0372
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Sildenafil is a selective phosphodiesterase-5 inhibitor that has been demonstrated to delay ventricular remodeling in humans and experimental animals. The aim of this prospective study was to assess the chronic effects of sildenafil administration on echocardiographic indices and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in dogs with naturally occurring, asymptomatic myxomatous mitral valve degeneration. Thirty client-owned dogs with ACVIM class B1 or B2 were enrolled. Dogs were randomly assigned to treatment (sildenafil 1-3 mg/kg, PO, BID for 180 days) or control groups. A total of 12 dogs completed the 180 days trial in the sildenafil group, whereas 10 dogs remained in control group. When comparing the difference from baseline values obtained over time between groups, the stroke volume (SV) at day 30 was significantly higher in the sildenafil group (P=0.038). The LA/Ao and the MR jet area were significantly lower beginning at day 30 (only MR jet area; P=0.006), day 90 (P=0.006 and P=0.027, respectively) and day 180 (P=0.029 and P=0.032, respectively). The 2D-LA was significantly lower at day 90 when compared with control group (P=0.028). The differences of NTproBNP from baseline were significantly lower when compared with control group at the same timepoint (D90, P=0.017 and D180, P=0.013). In conclusion, this study suggested that long-term treatment with sildenafil prevented aggravation of disease progression as suggested by several echocardiographic indices (i.e. SV, LA/Ao, MR jet area, 2D-LA) and reduced NTproBNP level at the indicated timepoints in dogs with asymptomatic mitral valve degeneration.
引用
收藏
页码:788 / 794
页数:7
相关论文
共 50 条
  • [1] Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration
    Pirintr, Prapawadee
    Saengklub, Nakkawee
    Limprasutr, Vudhiporn
    Sawangkoon, Suwanakiet
    Kijtawornrat, Anusak
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2017, 79 (09): : 1480 - 1488
  • [2] BRONCHOMALACIA IN DOGS WITH MYXOMATOUS MITRAL VALVE DEGENERATION
    Singh, M. K.
    Johnson, L. R.
    Kittleson, M. D.
    Pollard, R. E.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2011, 25 (03) : 649 - 649
  • [3] Bronchomalacia in Dogs with Myxomatous Mitral Valve Degeneration
    Singh, M. K.
    Johnson, L. R.
    Kittleson, M. D.
    Pollard, R. E.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2012, 26 (02) : 312 - 319
  • [4] Echocardiographic anatomy of the mitral valve in healthy dogs and dogs with myxomatous mitral valve disease
    Wesselowski, S.
    Borgarelli, M.
    Menciotti, G.
    Abbott, J.
    JOURNAL OF VETERINARY CARDIOLOGY, 2015, 17 (02) : 97 - 106
  • [5] THROMBOELASTOGRAPHY IN DOGS WITH ASYMPTOMATIC MYXOMATOUS MITRAL VALVE DISEASE
    Tarnow, I.
    Olsen, L. H.
    Moesgaard, S. G.
    Martinsen, A. U.
    Birkegaard, A. C.
    Kristensen, A. T.
    Wiinberg, B.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2010, 24 (03) : 673 - 673
  • [6] Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease
    Saengklub, Nakkawee
    Pirintr, Prapawadee
    Nampimoon, Thanida
    Kijtawornrat, Anusak
    Chaiyabutr, Narongsak
    FRONTIERS IN VETERINARY SCIENCE, 2021, 8
  • [7] Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease
    Sargent, Julia
    Muzzi, Ruthnea
    Mukherjee, Rajat
    Somarathne, Sharlene
    Schranz, Katherine
    Stephenson, Hannah
    Connolly, David
    Brodbelt, David
    Fuentes, Virginia Luis
    JOURNAL OF VETERINARY CARDIOLOGY, 2015, 17 (01) : 1 - 12
  • [8] Evaluation of genes associated with human myxomatous mitral valve disease in dogs with familial myxomatous mitral valve degeneration
    Meurs, K. M.
    Friedenberg, S. G.
    Williams, B.
    Keene, B. W.
    Atkins, C. E.
    Adin, D.
    Aona, B.
    DeFrancesco, T.
    Tou, S.
    Mackay, T.
    VETERINARY JOURNAL, 2018, 232 : 16 - 19
  • [9] Incremental predictive value of echocardiographic indices of right ventricular function in the assessment of long-term prognosis in dogs with myxomatous mitral valve disease
    Morita, T.
    Nakamura, K.
    Osuga, T.
    Takiguchi, M.
    JOURNAL OF VETERINARY CARDIOLOGY, 2022, 39 : 51 - 62
  • [10] Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease
    Vereb, Michelle
    Atkins, Clarke E.
    Adin, Darcy
    Blondel, Thomas
    Coffman, Melissa
    Lee, Seunggon
    Guillot, Emilie
    Ward, Jessica L.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2024, 38 (01) : 51 - 60